Showing results (431-440 of 511) with videos related to

Sort By:
Pageof 52
Frontiers in Endocrinology|December 2, 2024
Functional analysis of fibroblasts and macrophages in head and neck paragangliomasParamita Baruah, Jennifer L Marshall, Meriam Nefla, et al.
Veterinary Ophthalmology|March 12, 2024
Ophthalmic findings associated with Australian tick paralysis (holocyclotoxicity) in hospitalized domestic dogs and catsB D Reynolds, H G Nagel, E Perry, et al.
The New England Journal of Medicine|June 28, 2023
Mirikizumab as Induction and Maintenance Therapy for Ulcerative ColitisGeert D'Haens, Marla Dubinsky, Taku Kobayashi, et al.
Dalton Transactions (Cambridge, England : 2003)|June 11, 2024
Loading and thermal behaviour of ZIF-8 metal-organic framework-inorganic glass compositesAshleigh M Chester, Celia Castillo-Blas, Roman Sajzew, et al.
Inflammatory Bowel Diseases|April 4, 2025
Assessment and Impact of Age on the Safety and Efficacy of Etrasimod in Patients With Ulcerative Colitis: A Post Hoc Analysis of Data From the ELEVATE UC Clinical ProgramGary R Lichtenstein, Jessica R Allegretti, Edward V Loftus, et al.
Inflammatory Bowel Diseases|August 22, 2015
Prevalence and Risk Factors for Functional Vitamin B12 Deficiency in Patients with Crohn's DiseaseMark G Ward, Viraj C Kariyawasam, Sathis B Mogan, et al.
Internal Medicine Journal|February 11, 2020
A 14-year retrospective analysis of indications and outcomes of autologous haemopoietic stem cell transplantation in regional Queensland: a single-centre experienceElizabeth M Hamilton, Karthik D Nath, Venkat N Vangaveti, et al.
European Journal of Cancer (Oxford, England : 1990)|January 6, 2018
Tumour endothelial marker 1/endosialin-mediated targeting of human sarcomaY Guo, J Hu, Y Wang, et al.
Science (New York, N.Y.)|September 14, 2023
Conserved γδ T cell selection by BTNL proteins limits progression of human inflammatory bowel diseaseRobin J Dart, Iva Zlatareva, Pierre Vantourout, et al.
Journal of Crohn'S & Colitis|September 2, 2025
Faecal loss of vedolizumab is associated with UC severity, lower serum vedolizumab levels and rates of clinical response: Results from the FAVOUR studyMark A Samaan, Georgina Cunningham, Samuel Hsiang Lim, et al.
Pageof 52